Cancer
Hepatocellular carcinoma in Bengbu
蚌埠 肝细胞癌
1 hospital in Bengbu
Order: papers led on hepatocellular carcinoma, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for hepatocellular carcinoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Bengbu may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 41 papers ledNo open trial led
Hepatocellular carcinoma in every city Bengbu on the disease page, with the national map
open trials on hepatocellular carcinoma with a hospital in Bengbu
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with a listed hospital in Bengbu as lead sponsor or study site. 0 of them are led by a hospital in Bengbu. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingA Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Registry
- NCT07547553
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin
- RecruitingPhase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-11
- Registry
- NCT07176650
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingAnlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05862337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou
- RecruitingPhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Registry
- NCT05024214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai
- Not yet recruitingA Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2025-01
- Registry
- NCT06779461
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBengbu, Guangzhou, Lanzhou, Nanjing, Shanghai, Tianjin, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Bengbu
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| First Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院 | 8 | 51 open | 41 | 311 open | 2 | none | none | 0 | 1 | 1 | none | 5 | none | none | none | 1 | 4 | none | none | none | none | none | 0 | none | none | none | none | none | 0 | 1 | none | 2 | none | none | none | none | 0 | none | 2 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Bengbu.
- Nasopharyngeal carcinoma 8
- Oesophageal squamous cell carcinoma 51 open
- Hepatocellular carcinoma 41
- Stomach cancer 311 open
- Hepatoblastoma 2
- Osteosarcoma 0
- Gastrointestinal stromal tumour 1
- Neuroblastoma 1
- Multiple myeloma 5
- Beta thalassaemia 1
- Haemophilia A 4
- Myasthenia gravis 0
- Hepatic echinococcosis 0
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 2
- Behçet disease 0
- IgA nephropathy 2
- Primary biliary cholangitis 0
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for hepatocellular carcinoma.
Counts are listed hospitals only, not every hospital in each city.
- 123 kmHefei合肥3 hospitals for hepatocellular carcinoma
- 149 kmFuyangNone listed for hepatocellular carcinoma
- 157 kmXuzhou徐州2 hospitals for hepatocellular carcinoma
- 159 kmNanjing南京7 hospitals for hepatocellular carcinoma
- 168 kmHuai'an淮安1 hospital for hepatocellular carcinoma
- 195 kmYangzhou扬州1 hospital for hepatocellular carcinoma
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Bengbu on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.